Arena Pharma and United Therapeutics announce global license agreement for ralinepag
Arena Pharmaceuticals and United Therapeutics announced the companies have entered into a global license agreement for Arena's Phase 3 investigational drug candidate, ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of PAH. November 15, 2018